Foundation Medicine BioPharma Solutions

UniquelyFMI

FoundationOne®

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. 

For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. 

Community Guidelines: bit.ly/FMICommunityGuidelines

Google Ventures

Kleiner Perkins

Third Rock Ventures

Redmile Group

Deerfield Capital Management

Casdin Capital

Roche Venture Fund

Bill Gates

Evan Jones

Foundation Medicine

Foundation Medicine is a lead sponsor at this year’s 8th Annual Liquid Biopsy for Precision Oncology Summit! Looking forward to joining industry leaders to discuss how we are partnering and driving innovation in liquid biopsy and ctDNA monitoring. Don’t miss our plenary presentation, hosted workshop, and networking reception. Click the link to learn more and schedule a meeting: https://bit.ly/3uGDWTC

"Anyone with lungs can get lung cancer.” As a lung cancer survivor, physician, Dr. Sydney Barned advocates for more #awareness and empathy surrounding #lungcancer. Learn how Sydney and other oncology experts are setting the standard for research and treatment options: https://bit.ly/42D3AoP

Meet Tristen, our Senior Scientist in Assay Development. Her childhood fascination with forensic novels led her down a career path that unfolded in its own captivating narrative — an inspirational story of unexpected connections that shaped her journey. Read Tristen’s blog to hear more about the experiences that brought her to Foundation Medicine and her personal connection to our mission: https://bit.ly/3ut2QGb 

#WeAreFMI 

#ICYMI, Foundation Medicine’s Dr. Takara Scott led oncology leaders from LUNGevity Foundation and Moffitt Cancer Center in a discussion on the latest research and initiatives to help combat the disparities #lungcancer patients face today. During the event, panelists highlighted how important it is to ensure that the #innovation and #progress being made in lung cancer diagnostics are accessible to all patients. Watch the full Disparities in Lung Cancer event discussion here: https://lnkd.in/eUmkfer9

Domain Not Resolving

DNSSEC

Font Awesome

Cloudflare CDN

Cloudflare Hosting

Cloudflare JS

CDN JS

U.S. Server Location

Cloudflare Network Error Logging

Apple Mobile Web App Capable

Vice President, Deputy General Counsel

Andrea Marengi

Chief People Officer

Andrew Suchoff

Owner

azmol Choudhury

Vice President, Chief Information Security Officer

Bob Marcotte

Chief Executive Officer

Brian Alexander

Director, Assistant General Counsel

Christine Wahr

Fellow, Office of the CEO

David Spanos

Dmitry Solodov

Legal

Elizabeth Duckett

Chief Data Officer

Gaurav Singal

David Schenkein

Krishna Yeshwant

Mark Levin

Brook Byers

Michael J. Pellini

Mustafa Abdulali

Director of Operational Excellence

Jeffrey Ross

Medical Director, Interim Head of Pathology & Molecular Diagnostics

Lincoln Pasquina

Associate Director, SmartTrials

Daniel Malarek

Audra Knight

Sr. Manager, Employer Branding

Jeremy Deane

Chief Architect

Kathleen Gammon

Project Manager Scrum Master

Sanket Agrawal

Chief BioPharma Business Officer

United States Acquired Companies With More Than 50 Employees (Top 10K)

Health Care Acquired Companies With More Than 50 Employees

New England Companies With Less Than $500M in Revenue (Top 10K)

Massachusetts Companies With Fewer Than 1000 Employees (Top 10K)

Foundation Medicine plans to create clinical diagnostic tests that can use the latest in genetic sequencing technology to identify personalized cancer therapies for patients.

Series B - Foundation Medicine

Series A - Foundation Medicine

Venture Round - Foundation Medicine

Medical and Beauty Services and Agricultural Services

Cambridge

Massachusetts

United States

North America

Massive Bio and Foundation Medicine Partner to Optimize Clinical Trial Recruitment and Enrollment to Expand Access to Precision Cancer Care

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

Foundation Medicine Launches RNA Sequencing Test, FoundationOne®RNA, in the U.S.

Cancer Therapy and Testing Market Booming Worldwide With Leading Key Players -Invitae, Foundation Medicine ...

Methods and systems for predicting treatment response to mono-immunotherapy and …

Method for detecting patients with systematically under-estimated tumor …

Foundation Medicine consolidates employees in new Seaport HQ

Systems and methods for identifying hla variants

Multigene analysis of tumor samples

Braf gene fusions and uses thereof

A tissue-based comprehensive genomic profiling test that detects genomic alterations and fusions in cancer, aiding in therapy selection.

A blood-based test that identifies genomic alterations in circulating tumor DNA, providing insights for cancer treatment options.

A test for hematologic malignancies and sarcomas, focusing on gene fusion detection to guide treatment strategies.

An RNA sequencing test that detects fusions across 318 genes in solid tumors, complementing DNA-based fusion detection.

A large cancer genomic database used to evaluate tumor biology and support the development of new therapies.

Virtual meetings that discuss genomic test reports and their implications, enhancing understanding of complex cancer cases.

Kazakhstan

Asia

Turkey

Europe

China

Kenya

Africa

HTML5

Thawte SSL

Wistia

Office 365

jQuery

DigiCert

Microsoft Outlook

Google Fonts

Google Drive

Wordpress

Tempus is a company focused on precision medicine, offering services that utilize artificial intelligence for personalized patient care.

Tempus

Guardant Health is a biotech company specializing in non-invasive cancer diagnostics and monitoring.

Guardant Health

GRAIL is a healthcare company focused on early cancer detection through blood-based screening tests.

GRAIL

Foundation Medicine, Inc. develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas.

news impact assignment basic	general	Mar 8, 2024 4:18 AM	5b532eca
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 4:18 AM	9343aab8
company summary	general
signals	general	Mar 8, 2024 4:18 AM	eb96e0fa
crunchbase trigger	general	Nov 22, 2024 7:44 AM	9bab4675
crunchbase profile	general	Nov 22, 2024 8:49 AM	4fc7a3d0
li profile	general	Mar 8, 2024 4:18 AM	d220df04
translate crunchbase fundingrounds	general	Nov 22, 2024 10:54 AM	ceb43d91
peers	general	Mar 8, 2024 4:18 AM	857bf5d5
news basic	general	Mar 8, 2024 4:18 AM	d67dae3c
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FOUNDATIONMEDICINE

Foundation Medicine, Inc.